Metaplastic carcinoma of the breast: Clinicopathological features and treatment outcomes with long‑term follow up

Metaplastic breast carcinoma is an uncommon subtype of invasive ductal carcinoma with a tendency towards poorer clinical outcomes. Following ethical approval, the current study reviewed the institutional records of ~2,500 women with breast cancer. A total of 14 cases of metaplastic breast cancer wer...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2021-09, Vol.15 (3), Article 178
Main Authors: Gortman, Aron, Aherne, Noel J, Westhuyzen, Justin, Amalaseelan, Julan V, Dwyer, Patrick M, Hoffmann, Matthew, Last, Andrew T, Shakespeare, Thomas P
Format: Article
Language:English
Subjects:
Breast cancer
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical outcomes
Connective tissue diseases
Development and progression
Genotype & phenotype
Histopathology
Mastectomy
Medical prognosis
Metastasis
Molecular weight
Oncology
Oncology, Experimental
Patient outcomes
Patients
Radiation therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metaplastic breast carcinoma is an uncommon subtype of invasive ductal carcinoma with a tendency towards poorer clinical outcomes. Following ethical approval, the current study reviewed the institutional records of ~2,500 women with breast cancer. A total of 14 cases of metaplastic breast cancer were reviewed for management and treatment outcomes. The results demonstrated that patients had median follow up of 30 months, a 5-year disease-free survival of 57.1% and 5-year overall survival of 57.1%. The majority of patients had at least T2 disease and all tumours were high grade. Additionally, most patients were triple negative and nodal metastases were uncommon. Metaplastic breast cancer is an aggressive variant of invasive breast cancer. Most patients can be treated with breast conservation and survival parameters tend to be worse than more common breast cancer subtypes.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2021.2340